Content Hub

Key Takeaways from R&D Day 2026: From the Device Renaissance to Enlightenment

Written by Orchestra BioMed | Nov 19, 2026, 2:29:59 PM

Key Takeaways from R&D Day 2026: From the Device Renaissance to Enlightenment

Orchestra BioMed Investor Relations Blog | November 2026

 

On November 12, 2026, Orchestra BioMed hosted an R&D Day in New York City, welcoming more than 200 attendees both in person and online via webcast. Company management and leading physician experts presented the existing clinical evidence and trial design details behind our two pivotal trial-stage programs: the Virtue® Sirolimus AngioInfusion™ Balloon (“Virtue® SAB”) and Atrioventricular Interval Modulation Therapy (“AVIM Therapy”).

 

 

Featured Speakers & Contributors

  • David Hochman, Chairman, Chief Executive Officer and Co-Founder, Orchestra BioMed
  • Darren R. Sherman, President, Chief Operating Officer and Co-Founder, Orchestra BioMed
  • Allen Jeremias, MD, Virtue In-Stent Restenosis (“ISR”) Trial Co-Principal Investigator; Director, Cardiac Catheterization Laboratory, St. Francis Hospital & Heart Center
  • Duane Pinto, MD, MPH, Senior Clinical Advisor, Orchestra BioMed; Chief Medical Officer, JenaValve Technologies, Inc.
  • Vivek Reddy, MD, Executive Chairman, BACKBEAT Trial Steering Committee; Director of Cardiac Arrhythmia Services, Mount Sinai Hospital and Mount Sinai Health System
  • Marat Fudim, MD, MHS, Associate Professor of Cardiology, Advanced Heart Failure, Duke University Medical Center
  • Dean J. Kereiakes, MD, Virtue ISR Trial Co-Principal Investigator; Chairman of The Christ Hospital Heart and Vascular Institute, The Christ Hospital Health Network (was unable to attend but played a key role in content development)

 

The Agenda

David Hochman, Chairman, CEO and Co-Founder, opened the program with recent corporate updates and the themes framing the R&D Day event, including outlining Orchestra BioMed’s particular strategy and approach to research and development work. Darren R. Sherman, President and COO, then led the Virtue® SAB session, introducing the technology and key points of advantage before Allen Jeremias, MD, presented the clinical data; Dr. Jeremias and Duane Pinto, MD, then joined Sherman for a roundtable discussion.

Hochman opened the AVIM Therapy session with remarks on hypertension and unmet patient needs in the therapy’s target launch and potential expansion populations, followed by presentations from Vivek Reddy, MD, and Marat Fudim, MD, MHS. The program closed with a panel discussion and live Q&A, in which Sherman and Hochman moderated questions submitted by attendees, with Robert C. Kowal, MD, PhD, Vice President and General Manager of Cardiac Pacing Therapies at Medtronic, joining the discussion in response to several questions relevant to Medtronic’s commercial strategy for AVIM Therapy.

 

 

1. Funded through 2028 with a defined catalyst window ahead

Hochman opened with recent corporate updates, highlighting Orchestra BioMed’s oversubscribed public offering, which closed on November 9, 2026, with net proceeds of approximately $80.5 million. Together with $101.9 million in cash, cash equivalents and marketable securities at September 30, 2026, these proceeds extend the Company’s funded runway through 2028. Hochman noted that the Company is now “funded to execute on almost everything we’re going to talk about today.”

 

 

Another milestone in recent weeks was the completion of enrollment in the BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”), with 349 patients randomized across 92 sites in 15 countries. Orchestra also recently received written confirmation from the FDA that Medtronic will be able to submit AVIM Therapy for marketing approval as a PMA supplement.

Looking ahead, Hochman described a rich landscape of catalysts and milestones over the next two years: Orchestra BioMed and Medtronic intend to submit the BACKBEAT Trial primary endpoint results for late-breaking presentation consideration at HRS 2027 in May, and Medtronic plans to submit the PMA supplement to the FDA promptly after the presentation, assuming positive trial results. Subject to regulatory approval, that timeline supports a potential U.S. launch of AVIM Therapy as early as the first half of 2028, with global commercialization potentially following in the second half of that year.

In parallel, enrollment in the Virtue ISR Coronary Pivotal Trial (the “Virtue Trial”) is accelerating, with completion targeted by the end of 2027, positioning 12-month primary endpoint follow-up completion for as early as the end of 2028.

 

2. Building on proven foundations through collaboration

Hochman described a “renaissance” underway in two of the foundational technologies of cardiovascular medicine: the pacemaker, first implanted in 1958, and balloon angioplasty, first performed in 1977. He extended the metaphor to share perspective on Orchestra’s own innovations: just as the Renaissance gave rise to the Age of Enlightenment, when new ideas spread across geographies and throughout society, AVIM Therapy and Virtue® SAB aim to bring powerful new capabilities to these proven technologies, allowing them to improve outcomes as well as push into entirely new areas of treatment and to broader patient populations. With AVIM Therapy, that means a potent cardiac pacing therapy designed to immediately and substantially lower blood pressure and treat hypertensive heart disease; with Virtue® SAB, it means a potentially superior approach to delivering and extending the release of a proven drug in tissue to help heal the vessel.

 

 

R&D starts with unmet needs, and Orchestra’s two pivotal-stage programs are aimed at two of the biggest medical problems in the world: hypertension, the number one contributing risk factor for death worldwide, and coronary artery disease, the leading cause of death. Hochman described our approach in three parts: 1) build on proven foundations, 2) create powerful new capabilities, and 3) realize them through collaboration with strategic and research partners.

 

3. Virtue® SAB: pairing familiar tools with a new way to deliver sirolimus

Sherman opened the Virtue® SAB session with a walk through five decades of innovation in interventional cardiology: balloon angioplasty, bare-metal stents, drug-eluting stents and, most recently, drug-coated balloons (“DCBs”). Each step improved outcomes, but each also came with trade-offs. The drug on a drug-eluting stent, Sherman noted, is not there to treat the disease. The drug is there to treat the injury caused by the procedure, and a permanent implant carries a 2% to 4% year-over-year risk not just of reintervention, but also of additional long-term risks of heart attack, stroke and death.

 

 

Virtue® SAB builds on two proven elements: balloon angioplasty and sirolimus, an mTOR inhibitor in clinical use since 1993 and the drug of choice for drug-eluting coronary stents since the 2000s. Virtue® SAB uses a non-coated, microporous balloon to infuse a large liquid dose of SirolimusEFR, Orchestra’s proprietary submicron encapsulated particle formulation, directly into and along the length of the wall of the artery. “This is not a drug-coated balloon, and this is not a drug-eluting stent,” Sherman said. “The particle and the drug formulation is the innovation. The balloon is the familiar.”

Sherman also introduced the Virtue Trial, which is enrolling 740 patients with coronary ISR, randomized 1:1 against Boston Scientific’s AGENT paclitaxel-coated balloon, the first DCB approved in the U.S. for coronary use. The primary endpoint of the Virtue Trial is a non-inferiority comparison of target lesion failure at 12 months (a composite of cardiac death, nonfatal target vessel myocardial infarction and ischemia-driven target lesion revascularization).

What would success look like? In the roundtable that followed, the panel indicated that Virtue® SAB achieving the primary endpoint of non-inferiority with numerical separation would equal meaningful success and that, while Virtue® SAB might show statistically significant superiority at 12 months, it may not need to do so to change current practice. Dr. Jeremias noted that with current DCBs, “more than 80% of patients at one year are fine, but when you start following them out, the data is somewhat disappointing,” with more than a third of patients returning by three years. “If you can meaningfully reduce that number, I think it would be a win.” Dr. Pinto said a numerical advantage would be enough for him: “Numerically better in something where the curves start to diverge, I would assume they would continue to diverge. If early there’s a superiority signal, whether it’s p-value or not, and it’s numerically in [Virtue’s] favor, all the science lines up. That is enough for me to switch. I think everybody in the audience would say, well, wouldn’t I want the thing that’s better, and then let the stats play out to three years.”

 

4. AVIM Therapy: from the trunk of the tree to a defined launch population

Hochman opened the AVIM Therapy session by describing hypertension as the trunk of the tree of cardiovascular disease, from which heart attack, stroke, coronary artery disease, heart failure and damage to the kidneys and eyes all grow, and as ultimately not just a lifestyle disease, but a maladaptive part of us living longer that is especially difficult to manage in the older, comorbid patients Orchestra is targeting.

 

 

Each year, more than 1 million patients worldwide who receive a pacemaker also have hypertension. These pacemaker-indicated patients, who already need the device through which AVIM Therapy is delivered, are the launch population, and Medtronic, the global leader in cardiac pacing, holds exclusive global rights for that population and is responsible for regulatory approvals, manufacturing and global sales, marketing and support.

Following Hochman’s remarks, Dr. Reddy, one of the most influential electrophysiologists in the world, walked through the mechanism of AVIM Therapy, the results of the MODERATO II pilot study (“MODERATO II Study”) and the design of the BACKBEAT Trial, emphasizing that AVIM Therapy is “not a new device. We’re not talking about a new widget here. It’s fundamentally just a new way of pacing through existing pacemakers.” Dr. Fudim, an internationally recognized advanced heart failure cardiologist, then presented hemodynamic and echocardiographic data suggesting that the therapy’s benefits may extend beyond blood pressure to the structure and function of the heart.

What would success look like? The BACKBEAT Trial’s primary endpoint is the between-group difference in the change in 24-hour ambulatory systolic blood pressure at three months, and the trial is powered to detect a difference of 5 mmHg or greater. Asked during the Q&A whether the panel believed that threshold would be clinically meaningful, the panel’s answer was an unambiguous yes. “Even a 5-mmHg difference, if it’s a statistically significant difference, that’s what you see with most new antihypertensive drugs,” Dr. Reddy said, adding that in this population “we’re not talking about a new procedure. You’re literally just flipping a switch.”

Rob Kowal of Medtronic agreed: “Five millimeters is clinically significant. What we care about is what’s clinically significant for a patient that’s going to lead to a better outcome. There’s a wealth of data about how you can look at the benefits from a cardiovascular and stroke standpoint by how much you lower, and five is meaningful.”

Dr. Fudim put the number in context: renal denervation, another device-based therapy, has shown a 5 to 6 mmHg reduction versus control, so a double-digit reduction delivered “24/7, all day, every day” would be a much larger change. Dr. Reddy said that a double-digit drop like the one seen in the MODERATO II Study “would be astounding,” and Sherman summed up the Company’s view: if the BACKBEAT Trial simply repeats the MODERATO II Study result, “everyone agrees that’s a good thing.”

 

Looking Ahead

R&D Day brought together clinical and scientific insights on both of Orchestra’s pivotal trial-stage programs built on technologies clinicians already know, each adding a powerful new capability. With the BACKBEAT Trial fully enrolled, primary endpoint data planned for the second quarter of 2027, the Virtue Trial enrolling and a balance sheet that funds both programs through those milestones, our focus remains on disciplined execution alongside our partners and research collaborators.

Forthcoming posts will take a closer look at the Virtue® SAB and AVIM Therapy sessions, including key takeaways from the Q&A.

 

 

Missed R&D Day? Watch the full replay: https://investors.orchestrabiomed.com/events/event-details/2026-rd-day

 

Forward-Looking Statements

Certain statements included in the content distributed by Orchestra BioMed Holdings, Inc. (the “Company”) to which this disclaimer relates (including, but not limited to, visual, auditory, or written statements accessible through the link included in the Company’s digital communication) (the “Content”) that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the enrollment, timing, implementation, results and design of the Company’s ongoing pivotal trials, including the timing of completion of patient follow-up; the timing of the presentation of clinical data; the timing of regulatory submissions and potential regulatory approvals; the timing of potential commercial launches of the Company’s product candidates; the potential safety and efficacy of the Company’s product candidates; the size of the potential markets and patient populations for the Company’s product candidates, including potential expansion populations; the ability of the Company’s partnerships to accelerate clinical development; and the Company’s projected cash runway. These statements are based on various assumptions, whether or not identified in the Content, and on the current expectations of the Company’s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; the risk that the results of the Company’s clinical trials may not be positive or may not support regulatory approval; risks related to regulatory approval of the Company’s product candidates and ongoing regulation of the Company’s product candidates, if approved; the Company’s reliance on its strategic collaborators, including Medtronic, for the regulatory approval and commercialization of AVIM Therapy; the timing of, and the Company’s ability to achieve, expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading “Item 1A. Risk Factors” in the Company’s most recent annual report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), and under the heading “Item 1A. Risk Factors” in the Company’s subsequently filed quarterly reports on Form 10-Q.

The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of the Content. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made in the Content, except as required by law.